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Background
Trofile is a clinically validated HIV-1 co-receptor tropism
assay for selecting patients for therapy with entry inhibi-
tors targeting CCR5. Trofile determines whether a patient
virus population is CCR5 (R5), CXCR4 (X4) or dual (R5/
X4)/mixed (D/M)-tropic and has demonstrated utility in
clinical trials of CCR5 antagonists including maraviroc
and vicriviroc. Existing studies suggest that detection of
patients with lower levels of CXCR4-using variants may
further optimize patient selection for CCR5 antagonist
therapy. We therefore developed an enhanced sensitivity
Trofile assay with improved ability to detect low levels of
CXCR4-using virus.
Methods
Experiments were conducted to validate the performance
of the enhanced Trofile assay for patient management
applications in compliance with CAP and CLIA regula-
tions. The tropism of viral isolate and patient-derived
HIV-1 envelopes (Envs) were evaluated to assess assay
accuracy. Assay precision and reproducibility were
assessed by replicate testing and minor variant sensitivity
was determined using mixtures of patient-derived R5 and
X4 env clones.
Summary of results
Trofile enhancements increased detection sensitivity for
X4 Envs by approximately 30-fold on average. X4 clones
present at 0.3% were detected in 100% of assays. The
lower limit of X4 detection was env clone pair (patient)
dependent and ranged from 0.003–0.3%. Enhanced Tro-
file accurately determined the tropism of 46 patient sam-
ples and isolates representing multiple subtypes,
including 14/18 clonally analyzed patient samples with
X4 variants below the detection limit of the original Tro-
file assay. Intra-assay precision (100%) and inter-assay
reproducibility (99%) were demonstrated by concordant
results for 135/135 and 228/230 pair-wise comparisons
of R5, X4 and DM Envs and repeat testing of 46 patient
Env populations, respectively.
Conclusion
In conclusion, these validation experiments demonstrate
that the enhanced Trofile assay has improved sensitivity to
detect CXCR4-use in env clone mixtures and patient env
populations compared to the original Trofile assay, while
assay accuracy, precision and reproducibility are main-
tained. This increases the utility of the Trofile assay for
selecting patients for CCR5 antagonist therapy.
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